Scancell Holdings PLC (LSE:SCLP) Financings

Scancell Holdings PLC

Financings

RaiseDateIn US dollars
Private placement of private placement (PIPE Financing)
Update: US$39.1M · US$0.1205 a share · Leerink Partners +2
Dealers: Leerink Partners, TD Cowen, H.C. Wainwright & Co.
Buyers: Redmile Funds (44,813,278 Non-Voting Ordinary Shares); Vulpes (9,128,630 ADSs (representing 91,286,307 Ordinary Shares)); Dr Phil L'Huillier (24,896 ADSs)
Insiders: CEO Dr Phil L'Huillier to subscribe for 24,896 ADSs; related parties Redmile Funds and Vulpes also participating
Use of proceeds: Fund the registrational Phase 3 study of iSCIB1+ in advanced melanoma through key clinical milestones
Oct 9, 2026
Loan facility, partly convertible into Ordinary Shares, with warrants
Update: up to US$25M · warrants to subscribe for Ordinary Shares pro-rata to drawdowns, equal to 4.5% of each…
Buyers: BlackRock (lender under a loan facility of up to $25.0 million); funds and accounts managed by BlackRock (Lender under loan facility of up to US$25,000,000); Kreos Capital VIII Aggregator SCSp (Warrants pro rata to drawdowns under the Loan Facility)
Use of proceeds: To initiate and execute the global registrational Phase 3 trial of lead programme iSCIB1+
Oct 9, 2026
Private placement of new Ordinary Shares
Update: about US$12M · GBX 9 a share · Panmure Liberum Limited
Dealers: Panmure Liberum Limited (lead)
Jul 24, 2026
Ordinary Shares
Update: up to US$3M · GBX 9 a share
Jul 24, 2026
New ordinary shares (Retail Offer Shares)
Closed: £1M raised · GBX 10.5 a share · Winterflood Securities Limited
Dealers: Winterflood Securities Limited
Use of proceeds: Further working capital and balance sheet strength
Dec 9, 2024US$1.28M
Private placement of new ordinary shares (Placing Shares)
Made bigger: £10.3M · GBX 10.5 a share · Panmure Liberum Limited +1
Dealers: Panmure Liberum Limited (co-lead), WG Partners LLP (co-lead)
Buyers: Redmile Group, LLC (28,571,428 Placing Shares); Vulpes Investment Management (10,476,190 Placing Shares)
Insiders: Related parties Redmile and Vulpes, substantial shareholders, conditionally subscribing for 28,571,428 and 10,476,190 Placing Shares respectively
Use of proceeds: Progress lead cancer vaccine SCIB1 and next generation iSCIB1+, and extend cash runway to H2 2026
Dec 5, 2024US$13.13M
Private placement of new ordinary shares (Subscription Shares)
Update: about £20,000 · GBX 10.5 a share
Buyers: Sath Nirmalananthan (190,476 Ordinary Shares)
Insiders: Director and CFO Sath Nirmalananthan conditionally subscribed for 190,476 Ordinary Shares
Dec 5, 2024US$25,395

Read by 6ix AI from the company's releases